Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

EnQuest expects solid net production figures in FY25

(Sharecast News) - Exploration and production company EnQuest said FY25 production would likely be stronger than the level seen in FY24 on Wednesday. EnQuest said net production from its existing portfolio averaged 44,200 barrels of oil equivalent per day in January and stated pro forma 2025 production was now expected to be between 40,000 and 45,000 boepd, compared to 40,736 boepd in 2024.

The London-listed firm also said it was looking to use its tax position to unlock "value-accretive" growth in the UK as it continues to work towards a transaction in the North Sea and another potential new country entry in South East Asia.

Chief executive Amjad Bseisu said: "EnQuest's foundation for growth remains robust and we are progressing several UK transaction processes, each focused on monetising the group's UK tax asset.

"Building shareholder value remains at the heart of our capital allocation decisions and we will provide an update on the group's shareholder return plans when we announce our final audited results in March."

As of 0920 GMT, Enquest shares were up 0.69% at 11.84p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.